Shares of Wockhardt maintained its uptrend from yesterday, today stock jumped over 15%, touching the weekly high of Rs350, after company has received US Food and Drug Administration's approval to market generic Fluticasone nasal spray used for treating allergic nasal inflammation in the American market.
The market size for the drug in the US is about $600 million and three other generic players are selling the drug in the US currently. A 15% market share for Wockhardt will add nearly $90 million to the bottom line. The drug has margins of nearly 60 per cent which translates into a topline of $50 million for the company. This will translate into earnings per share (EPS) of Rs 20 for FY13.
....more info
The market size for the drug in the US is about $600 million and three other generic players are selling the drug in the US currently. A 15% market share for Wockhardt will add nearly $90 million to the bottom line. The drug has margins of nearly 60 per cent which translates into a topline of $50 million for the company. This will translate into earnings per share (EPS) of Rs 20 for FY13.
....more info